Faculty of Health Science, University of Southern Denmark, Odense, Denmark.
Community Health Development Nepal, Kathmandu, Nepal.
Sci Rep. 2021 Jan 22;11(1):2113. doi: 10.1038/s41598-021-81057-2.
The escalating burden of diabetes is increasing the risk of contracting tuberculosis (TB) and has a pervasive impact on TB treatment outcomes. Therefore, we conducted this systematic review and meta-analysis to examine the burden of diabetes among TB patients and assess its impact on TB treatment in South Asia (Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, India, Pakistan, and Sri Lanka). PubMed, Excerpta Medica Database (EMBASE), and CINAHL databases were systematically searched for observational (cross-sectional, case-control and cohort) studies that reported prevalence of diabetes in TB patients and published between 1 January 1980 and 30 July 2020. A random-effect model for computing the pooled prevalence of diabetes and a fixed-effect model for assessing its impact on TB treatment were used. The review was registered with PROSPERO number CRD42020167896. Of the 3463 identified studies, a total of 74 studies (47 studies from India, 10 from Pakistan, four from Nepal and two from both Bangladesh and Sri-Lanka) were included in this systematic review: 65 studies for the prevalence of diabetes among TB patients and nine studies for the impact of diabetes on TB treatment outcomes. The pooled prevalence of diabetes in TB patients was 21% (95% CI 18.0, 23.0; I2 98.3%), varying from 11% in Bangladesh to 24% in Sri-Lanka. The prevalence was higher in studies having a sample size less than 300 (23%, 95% CI 18.0, 27.0), studies conducted in adults (21%, 95% CI 18.0, 23.0) and countries with high TB burden (21%, 95% CI 19.0, 24.0). Publication bias was detected based on the graphic asymmetry of the funnel plot and Egger's test (p < 0.001). Compared with non-diabetic TB patients, patients with TB and diabetes were associated with higher odds of mortality (Odds Ratio (OR) 1.7; 95% CI 1.2, 2.51; I2 19.4%) and treatment failure (OR 1.7; 95% CI 1.1, 2.4; I2 49.6%), but not associated with Multi-drug resistant TB (OR 1.0; 95% CI 0.6, 1.7; I2 40.7%). This study found a high burden of diabetes among TB patients in South Asia. Patients with TB-diabetes were at higher risk of treatment failure and mortality compared to TB alone. Screening for diabetes among TB patients along with planning and implementation of preventive and curative strategies for both TB and diabetes are urgently needed.
在南亚(阿富汗、孟加拉国、不丹、马尔代夫、尼泊尔、印度、巴基斯坦和斯里兰卡),糖尿病负担的不断增加增加了患结核病(TB)的风险,并对 TB 治疗结果产生了普遍影响。因此,我们进行了这项系统评价和荟萃分析,以检查 TB 患者中糖尿病的负担,并评估其对 TB 治疗的影响。我们系统地检索了 PubMed、Excerpta Medica Database(EMBASE)和 CINAHL 数据库,以查找报告 1980 年 1 月 1 日至 2020 年 7 月 30 日期间 TB 患者中糖尿病患病率的观察性(横断面、病例对照和队列)研究。使用随机效应模型计算糖尿病的汇总患病率,并使用固定效应模型评估其对 TB 治疗的影响。该综述已在 PROSPERO 登记,编号为 CRD42020167896。在 3463 项确定的研究中,共有 74 项研究(来自印度的 47 项研究、来自巴基斯坦的 10 项研究、来自尼泊尔的 4 项研究和来自孟加拉国和斯里兰卡的 2 项研究)被纳入本系统评价:65 项研究用于评估 TB 患者中糖尿病的患病率,9 项研究用于评估糖尿病对 TB 治疗结果的影响。TB 患者中糖尿病的汇总患病率为 21%(95%CI 18.0,23.0;I2 98.3%),范围从孟加拉国的 11%到斯里兰卡的 24%。在样本量小于 300 的研究(23%,95%CI 18.0,27.0)、在成年人中进行的研究(21%,95%CI 18.0,23.0)和结核病负担高的国家进行的研究中,患病率更高(21%,95%CI 19.0,24.0)。基于漏斗图的图形不对称和 Egger 检验(p<0.001)检测到发表偏倚。与非糖尿病 TB 患者相比,患有 TB 和糖尿病的患者死亡的几率更高(优势比(OR)1.7;95%CI 1.2,2.51;I2 19.4%)和治疗失败(OR 1.7;95%CI 1.1,2.4;I2 49.6%),但与耐多药结核病(OR 1.0;95%CI 0.6,1.7;I2 40.7%)无关。本研究发现南亚地区 TB 患者中糖尿病负担很高。与单纯 TB 相比,合并 TB 糖尿病的患者治疗失败和死亡的风险更高。迫切需要对 TB 患者进行糖尿病筛查,并制定和实施针对 TB 和糖尿病的预防和治疗策略。